[1]
März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterology report. 2015 Nov:3(4):298-302. doi: 10.1093/gastro/gov044. Epub 2015 Sep 30
[PubMed PMID: 26424828]
[2]
Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. The British journal of surgery. 2012 May:99(5):699-705. doi: 10.1002/bjs.8679. Epub 2012 Jan 27
[PubMed PMID: 22287157]
[3]
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best practice & research. Clinical obstetrics & gynaecology. 2017 May:41():3-14. doi: 10.1016/j.bpobgyn.2016.08.006. Epub 2016 Oct 3
[PubMed PMID: 27743768]
[4]
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer treatment and research. 1996:82():359-74
[PubMed PMID: 8849962]
[5]
Spratt JS, Adcock RA, Sherrill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer research. 1980 Feb:40(2):253-5
[PubMed PMID: 7356508]
[6]
Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Annals of surgical oncology. 2008 Sep:15(9):2426-32. doi: 10.1245/s10434-008-9966-2. Epub 2008 Jun 3
[PubMed PMID: 18521686]
Level 1 (high-level) evidence
[7]
Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ, research committee of the European Society of Coloproctology. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2017 Mar:19(3):224-236. doi: 10.1111/codi.13593. Epub
[PubMed PMID: 28008728]
Level 3 (low-level) evidence
[8]
Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer treatment and research. 1996:82():53-63
[PubMed PMID: 8849943]
[9]
de Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer chemotherapy and pharmacology. 2003 Aug:52(2):108-12
[PubMed PMID: 12759776]
[10]
Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Myers CE. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer research. 1981 May:41(5):1916-22
[PubMed PMID: 7214359]
[11]
Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer journal (Sudbury, Mass.). 2009 May-Jun:15(3):216-24. doi: 10.1097/PPO.0b013e3181a58d95. Epub
[PubMed PMID: 19556908]
[12]
de Bree E, Helm CW. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. Expert review of anticancer therapy. 2012 Jul:12(7):895-911. doi: 10.1586/era.12.72. Epub
[PubMed PMID: 22845405]
[13]
Oseledchyk A, Zivanovic O. Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer. Oncology (Williston Park, N.Y.). 2015 Sep:29(9):695-701
[PubMed PMID: 26384807]
[14]
de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 2007:169():39-51
[PubMed PMID: 17506248]
[15]
Brown SL, Hunt JW, Hill RP. Differential thermal sensitivity of tumour and normal tissue microvascular response during hyperthermia. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 1992 Jul-Aug:8(4):501-14
[PubMed PMID: 1402130]
[16]
Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World journal of gastroenterology. 2016 Jan 21:22(3):1114-30. doi: 10.3748/wjg.v22.i3.1114. Epub
[PubMed PMID: 26811651]
[17]
Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014 Jan:40(1):12-26. doi: 10.1016/j.ejso.2013.10.019. Epub 2013 Nov 5
[PubMed PMID: 24290371]
Level 1 (high-level) evidence
[18]
Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2015 Dec:41(12):1578-89. doi: 10.1016/j.ejso.2015.08.172. Epub 2015 Sep 25
[PubMed PMID: 26453145]
Level 1 (high-level) evidence
[19]
Klos D, Riško J, Stašek M, Loveček M, Hanuliak J, Skalický P, Lemstrová R, Mohelníková BD, Študentová H, Neoral Č, Melichar B. Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies. Casopis lekaru ceskych. 2018 Dec 17:157(8):419-428
[PubMed PMID: 30754979]
[20]
Garland-Kledzik M, Uppal A, Naeini YB, Stern S, Erali R, Scholer AJ, Khader AM, Santamaria-Barria JA, Cummins-Perry K, Zhou Y, Votanopoulos KI, Shen P, Levine EA, Bilchik AJ. Prognostic Impact and Utility of Immunoprofiling in the Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC). Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2021 Jan:25(1):233-240. doi: 10.1007/s11605-020-04886-y. Epub 2020 Dec 2
[PubMed PMID: 33269456]
[21]
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Jul 10:30(20):2449-56. doi: 10.1200/JCO.2011.39.7166. Epub 2012 May 21
[PubMed PMID: 22614976]
[22]
Dehal A, Smith JJ, Nash GM. Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. Journal of gastrointestinal oncology. 2016 Feb:7(1):143-57. doi: 10.3978/j.issn.2078-6891.2015.112. Epub
[PubMed PMID: 26941992]
[23]
Lambert LA. Looking up: Recent advances in understanding and treating peritoneal carcinomatosis. CA: a cancer journal for clinicians. 2015 Jul-Aug:65(4):284-98. doi: 10.3322/caac.21277. Epub 2015 May 4
[PubMed PMID: 25940594]
Level 3 (low-level) evidence
[24]
da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. Journal of the American College of Surgeons. 2006 Dec:203(6):878-86
[PubMed PMID: 17116556]
[25]
Piso P, Nedelcut SD, Rau B, Königsrainer A, Glockzin G, Ströhlein MA, Hörbelt R, Pelz J. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients. Annals of surgical oncology. 2019 Jan:26(1):148-154. doi: 10.1245/s10434-018-6992-6. Epub 2018 Nov 19
[PubMed PMID: 30456672]
[26]
Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. Journal of surgical oncology. 2005 Jun 15:90(4):220-5
[PubMed PMID: 15906364]
[27]
Morano WF, Khalili M, Chi DS, Bowne WB, Esquivel J. Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions-A systematic review. Journal of surgical oncology. 2018 Feb:117(2):245-259. doi: 10.1002/jso.24813. Epub 2017 Nov 9
[PubMed PMID: 29120491]
Level 3 (low-level) evidence
[28]
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Annals of surgical oncology. 2011 Jun:18(6):1575-81. doi: 10.1245/s10434-011-1631-5. Epub 2011 Mar 23
[PubMed PMID: 21431408]
Level 1 (high-level) evidence
[29]
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. The New England journal of medicine. 2018 Jan 18:378(3):230-240. doi: 10.1056/NEJMoa1708618. Epub
[PubMed PMID: 29342393]
[30]
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, Juzyna B, de Forges H, Paineau J, Glehen O, UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology. 2021 Feb:22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18
[PubMed PMID: 33476595]
Level 1 (high-level) evidence
[31]
Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H, Kerger J. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Annals of surgical oncology. 2012 Jul:19(7):2186-94. doi: 10.1245/s10434-012-2264-z. Epub 2012 Mar 7
[PubMed PMID: 22395983]
[32]
Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Annals of surgical oncology. 2014 May:21(5):1501-5. doi: 10.1245/s10434-013-3061-z. Epub 2013 Jun 21
[PubMed PMID: 23793364]
Level 3 (low-level) evidence
[33]
Désolneux G, Mazière C, Vara J, Brouste V, Fonck M, Béchade D, Bécouarn Y, Evrard S. Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PloS one. 2015:10(3):e0122816. doi: 10.1371/journal.pone.0122816. Epub 2015 Mar 31
[PubMed PMID: 25825874]
[34]
Shida D, Yoshida T, Tanabe T, Tsukamoto S, Ochiai H, Kanemitsu Y. Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis. Annals of surgical oncology. 2018 Jun:25(6):1646-1653. doi: 10.1245/s10434-018-6436-3. Epub 2018 Mar 23
[PubMed PMID: 29572704]
[35]
Shida D, Tsukamoto S, Ochiai H, Kanemitsu Y. Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy. Annals of surgical oncology. 2018 Jan:25(1):173-178. doi: 10.1245/s10434-017-6133-7. Epub 2017 Oct 23
[PubMed PMID: 29063295]
[36]
Repullo DJ, Barbois S, Leonard D, Bohlok A, Van den Audenaeren ET, Hendlisz A, Van den Eynde M, Donckier V, Kartheuser A, Liberale G. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2021 Jul:47(7):1661-1667. doi: 10.1016/j.ejso.2021.01.018. Epub 2021 Feb 3
[PubMed PMID: 33602530]
Level 2 (mid-level) evidence
[37]
Gronau F, Jara M, Feldbrügge L, Wolf V, Oeff A, Rau B. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 2021 Jun:92(6):522-527. doi: 10.1007/s00104-021-01371-3. Epub 2021 Feb 23
[PubMed PMID: 33620502]
[38]
Rosa F, Galiandro F, Ricci R, Di Miceli D, Longo F, Quero G, Tortorelli AP, Alfieri S. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Langenbeck's archives of surgery. 2021 Jun:406(4):1071-1080. doi: 10.1007/s00423-021-02137-5. Epub 2021 Feb 21
[PubMed PMID: 33611693]
[39]
Lei Z, Wang J, Li Z, Li B, Luo J, Wang X, Wang J, Ba M, Tang H, He Q, Liao Q, Yang X, Guan T, Liang H, Cui S, On Behalf Of The Chinese Peritoneal Oncology Study Group. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A multicenter propensity score-matched cohort study. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2020 Dec 31:32(6):794-803. doi: 10.21147/j.issn.1000-9604.2020.06.12. Epub
[PubMed PMID: 33447001]